Foundayo Tracker.
The first FDA-approved oral GLP-1 tablet that does not need to be taken on an empty stomach. FDA-approved 1 April 2026 as Foundayo (orforglipron) tablets. Here is what the label and published trials say, and how GLP AI tracks it.
4.8★ · 3,200+ ratings on the App Store and Google Play
Foundayo (Orforglipron) is FDA-approved. FDA-approved 1 April 2026 as Foundayo (orforglipron) tablets. This page is education from the FDA announcement, the prescribing information, and published trials — not medical advice. GLP AI does not prescribe or dispense medication.
Foundayo, from the published record.
Oral small-molecule GLP-1 receptor agonist — a non-peptide pill, so no food or water restrictions (unlike Rybelsus). Daily oral tablet — taken any time of day, no empty-stomach rule.
| US approval | FDA approved Foundayo (orforglipron) on 1 April 2026 for adults with obesity, or adults with overweight plus at least one weight-related comorbid condition, used with a reduced-calorie diet and increased physical activity |
| How it is taken | Once-daily tablet. Starting dose 0.8 mg, then 2.5 mg and 5.5 mg after at least 30 days at each step; may increase to 9 mg, 14.5 mg, or 17.2 mg based on response and tolerability (Foundayo prescribing information) |
| Phase 3 trial (obesity, before approval) | ATTAIN-1 reported about 12.4% mean weight loss at 72 weeks on the highest trial dose (36 mg daily). That trial dose is not the approved Foundayo schedule. |
| Phase 3 trial (type 2 diabetes) | ACHIEVE-1: A1C reductions of roughly 1.3–1.6% across trial doses |
Sources: FDA approval announcement — Foundayo (orforglipron), 1 April 2026 · Foundayo (orforglipron) Prescribing Information · Phase 2 obesity trial — Wharton et al., NEJM 2023 · ATTAIN-1 Phase 3 trial record (ClinicalTrials.gov)
How Foundayo differs from other GLP-1s.
Rybelsus (oral semaglutide) is a peptide that survives the stomach only with a strict empty-stomach routine. Foundayo (orforglipron) is a small molecule — absorbed like a typical pill, taken any time, with no empty-stomach rule. Trial averages sit below injectable tirzepatide; the practical difference is an approved daily tablet without the morning ritual.
GLP AI is Foundayo-ready.
You can track Foundayo in GLP AI today via custom medications — doses, meals with the 0–100 GLP-1 Meal Score, side effects, and weight on one timeline. Dedicated dose schedules and the medication level chart land as first-class support; history you log now carries over.
Foundayo — FAQs.
What is Foundayo (Orforglipron)?+
Foundayo (Orforglipron) is an oral GLP-1 medication from Eli Lilly — oral small-molecule GLP-1 receptor agonist — a non-peptide pill, so no food or water restrictions (unlike Rybelsus). FDA-approved 1 April 2026 as Foundayo (orforglipron) tablets. This page is education from the FDA announcement, the prescribing information, and published trials — not medical advice.
Can I get Foundayo now?+
Foundayo (Orforglipron) is FDA-approved. Whether a clinician prescribes it and whether a pharmacy can fill it is a care-team question. GLP AI does not prescribe, sell, or dispense medication. Products sold under the research name outside a legitimate prescription are still a safety risk.
Can GLP AI track Foundayo?+
Yes — GLP AI supports custom medications, so you can log Foundayo doses, meals with the 0–100 GLP-1 Meal Score, side effects, and weight on one timeline today. Dedicated dose schedules and the medication level chart are added as first-class support lands.
What if I am still on a different GLP-1?+
That is a conversation for your doctor. Approved options include semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), and Foundayo (orforglipron). Whichever you are prescribed, GLP AI tracks shots or pills, and switching later keeps your history intact.
Is orforglipron approved by the FDA?+
Yes. The FDA approved Foundayo (orforglipron) tablets on 1 April 2026 for long-term weight reduction in adults with obesity, or adults with overweight plus at least one weight-related comorbid condition, used with diet and activity. Approval is not the same as a prescription or a guarantee your pharmacy has it — that is a clinician and pharmacy question. GLP AI does not prescribe.
How is Foundayo different from Rybelsus?+
Both are daily oral GLP-1s. Rybelsus is oral semaglutide and requires an empty stomach, a small amount of water, and a 30-minute wait. Foundayo is orforglipron, a small molecule with no food or water restrictions in the FDA description of how it is taken.
How much weight loss does orforglipron show?+
The FDA reported statistically significant weight reduction versus placebo in two randomized trials used for approval. ATTAIN-1, a Phase 3 obesity trial before approval, reported about 12.4% mean weight loss at 72 weeks on a 36 mg daily trial dose — that trial dose is not the approved Foundayo schedule (0.8 mg stepping up to 17.2 mg). Individual results vary; this page is education, not a prediction.
Go further with GLP AI.
Track it once. Understand it forever.
Start tracking your oral GLP-1 — shots or pills live on the same timeline.